Metabolomics During ElectroConvulsivoTherapy

Launched by HÔPITAL LE VINATIER · Jul 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how changes in the body's metabolic profile, measured through blood tests, can help predict how well patients respond to electroconvulsive therapy (ECT) for major depression. Researchers believe that understanding these metabolic changes could provide insights into the biological processes behind depression and improve treatment outcomes. The trial is open to adults aged 65 to 74 who have a major depressive episode, whether due to major depressive disorder or bipolar disorder, and who have not improved with at least two different antidepressants.

Eligible participants will need to provide written consent and meet certain health criteria. They should have a significant depression score and be currently receiving ECT as a treatment option. However, individuals with certain mental health conditions, neurological disorders, or severe inflammatory diseases will not be included in the study. Participants can expect to have their blood tested at various points during their ECT treatment to track how their metabolism changes and how that might relate to their recovery from depression.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major depressive episode according to DSM-5 criteria
• • Diagnosis of major depressive disorder or bipolar disorder
• • MADRS score \>22
• • having given written, free and informed consent
• • without protective measures
• • resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks
• • current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure
• Exclusion Criteria - Cannot be included in the study, people:
• • whose consent is not admissible or who refuse to participate in the study
• • deprived of liberty by judicial or administrative decision
• • For which there is a particular risk contraindicating the cure of ECT
• • Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder
• • suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and/or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5
• • suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5